STOCK TITAN
  1. Home
  2. Sec-filings
  3. JNJ
  4. [ARS] JOHNSON & JOHNSON SEC Filing

[ARS] JOHNSON & JOHNSON SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS

Rhea-AI Filing Summary

Analyzing...
ARS - JOHNSON & JOHNSON

ARS Filing - JOHNSON & JOHNSON

This filing is available as a PDF document.

Filing Type: ARS

Company: JOHNSON & JOHNSON (JNJ)

Acceptance Date: 2026-03-11T06:23:05.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Johnson & Johnson

NYSE:JNJ

View JNJ Stock Overview →

JNJ Rankings

#18 Ranked by Market Cap
#938 Ranked by Dividends
#361 52-Week Gainer
#314 YTD Gainer
#692 Monthly Gainer
#1226 Ranked by Short %Change

JNJ Latest News

Mar 5, 2026
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Mar 3, 2026
/C O R R E C T I O N -- Johnson & Johnson/
Mar 3, 2026
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Mar 2, 2026
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
Feb 26, 2026
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

JNJ Latest SEC Filings

Mar 11, 2026
[DEF 14A] JOHNSON & JOHNSON Definitive Proxy Statement
Mar 3, 2026
[Form 4] JOHNSON & JOHNSON Insider Trading Activity
Feb 27, 2026
[144] JOHNSON & JOHNSON SEC Filing
Feb 23, 2026
[Form 4] JOHNSON & JOHNSON Insider Trading Activity
Feb 20, 2026
[144] JOHNSON & JOHNSON SEC Filing

JNJ Stock Data

587.32B
2.40B
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW BRUNSWICK